David Colligan
Scottish National Blood Transfusion Service
5 Papers
5 Citations
David Colligan is an academic researcher from Scottish National Blood Transfusion Service. The author has contributed to research in topics: Mesenchymal stem cell & Transplantation. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
Human umbilical cord perivascular cells improve human pancreatic islet transplant function by increasing vascularization
Shareen Forbes,Andrew R Bond,Kayleigh L. Thirlwell,Kayleigh L. Thirlwell,Paul Burgoyne,Paul Burgoyne,Paul Burgoyne,Kay Samuel,June Noble,Gary Borthwick,David Colligan,Neil W. A. McGowan,Philip J. Starkey Lewis,Alasdair R. Fraser,Joanne C. Mountford,Roderick N. Carter,Nicholas M. Morton,Marc Turner,Gerard J. Graham,John M. Campbell,John M. Campbell +20 more
TL;DR: The immunosuppressive and proregenerative properties of HUCPVCs demonstrated long-term positive effects on graft function in vivo, indicating that they may improve long- term human islet allotransplantation outcomes.
43
Optimal use of blood and innovative approaches to stem cells, regenerative medicine and donor recruitment.
TL;DR: Presentations ranged from the challenges of recruiting young donors, forecasting future blood demand and celebrating the success of the better blood transfusion program, to the potential future developments in regenerative medicine particularly the potential of mesenchymal stromal cells.
5
Mesenchymal Stem/Stromal Cells: DEVELOPMENT OF A GMP BANKING PROCESS FOR UMBILICAL CORD MESENCHYMAL STROMAL CELLS (UC-MSCS) AND USE OF UC-MSC IN CHARACTERISATION ASSAYS, FUNCTIONAL ASSAYS AND GENE EDITING STUDIES
Angela McCahill,Kay Hewit,K. Samuel,David Colligan,Alison Condie,Avery Thomson,Joanne C. Mountford +6 more
TL;DR: A GMP process to bank umbilical cord MSCs with the potential to generate future banks of primary UC-MSCS with genetically enhanced pro-angiogenic, immunoregulatory and/or anti-inflammatory activities and gene editing by CRISPR/Cas9 technology is tested.
Mesenchymal stromal cells as multifunctional cellular therapeutics – a potential role for extracellular vesicles
Jillian Stephen,Elena Lopez Bravo,David Colligan,Alasdair R. Fraser,Juraj Petrik,John D.M. Campbell +5 more
TL;DR: The development of GMP-grade production protocols and effective characterisation of MSC extracellular vesicles is essential to their successful use as immune modulating therapeutic agents, and the current status of the research in this area is outlined.
Pancreas-derived mesenchymal stromal cells share immune response-modulating and angiogenic potential with bone marrow mesenchymal stromal cells and can be grown to therapeutic scale under Good Manufacturing Practice conditions.
Kayleigh L. Thirlwell,Kayleigh L. Thirlwell,David Colligan,Joanne C. Mountford,Kay Samuel,Laura Bailey,Nerea Cuesta-Gomez,Kay Hewit,Kay Hewit,Christopher Kelly,Christopher C. West,Neil W. A. McGowan,John Casey,Gerard J. Graham,Marc Turner,Shareen Forbes,John M. Campbell,John M. Campbell +17 more
TL;DR: LPIs express patterns of chemokines and pro-regenerative factors similar to those of BM MSCs and, importantly, are equally able to attract immune cells in vitro and in vivo and suppress T-cell proliferation in vitro.